Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXP004
- Development stage
- Preclinical
- Lead developer
- Nuformix
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NXP004 is a novel, proprietary cocrystal formulation of the PARP inhibitor olaparib, developed by Nuformix. By utilizing cocrystal technology, NXP004 is designed to enhance the dissolution and bioavailability of olaparib compared to the currently marketed formulation (Lynparza). The drug targets poly (ADP-ribose) polymerase (PARP) enzymes, which are critical for DNA repair. Inhibiting PARP leads to the accumulation of DNA damage and cell death, particularly in cancer cells with existing DNA repair deficiencies, such as those with BRCA mutations. NXP004 is currently in the preclinical stage of development for various oncology indications, with the goal of providing a superior pharmacokinetic profile over existing olaparib treatments.
- Other names
- olaparib cocrystal
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on NXP004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXP004.